secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066416
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports Q1 net loss $20.3M; AlloNK IND cleared for autoimmune basket trial
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $166.0M as of March 31, 2025; cash runway into Q2 2027.
- R&D expenses $17.1M (vs $11.2M YoY); net loss $20.3M (vs $14.0M YoY).
- IND cleared for Phase 2a basket trial of AlloNK+rituximab in refractory RA, Sjögren's, myositis, scleroderma; site initiation underway.
- Longer-term B-NHL data at ASGCT shows CR rates and median DOR in line with approved auto-CAR-T therapies.
- Appointed Subhashis Banerjee, M.D. as CMO on April 8, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/0000950170-25-066416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/artv-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer